{"filing":{"accession_number":"0001193125-26-299165","cik":"0001831828","ticker":"VERA","company_name":"Vera Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-09","report_date":null,"primary_document":"vera-20260709.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1831828/000119312526299165/vera-20260709.htm"},"events":[{"id":17211,"run_id":15397,"accession_number":"0001193125-26-299165","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"The filing discloses the appointment of Nancy Bowman, M.D., Ph.D., as Chief Regulatory Officer effective August 3, 2026, succeeding William Turner. While Turner's transition to Special Advisor represents a departure from his CRO role, the principal disclosed action centers on the appointment of a new CRO—a material executive officer position at a therapeutic company where regulatory affairs are critical to operations and strategy.","company_name":"Vera Therapeutics, Inc.","ticker":"VERA","filing_date":"2026-07-09","form":"8-K","submitted_at":null,"items":[{"id":15580,"accession_number":"0001193125-26-299165","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the appointment of Nancy Bowman, M.D., Ph.D., as Chief Regulatory Officer effective August 3, 2026, succeeding William Turner. While Turner's transition to Special Advisor represents a departure from his CRO role, the principal disclosed action centers on the appointment of a new CRO—a material executive officer position at a therapeutic company where regulatory affairs are critical to operations and strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T13:04:44.426397+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15580,"accession_number":"0001193125-26-299165","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the appointment of Nancy Bowman, M.D., Ph.D., as Chief Regulatory Officer effective August 3, 2026, succeeding William Turner. While Turner's transition to Special Advisor represents a departure from his CRO role, the principal disclosed action centers on the appointment of a new CRO—a material executive officer position at a therapeutic company where regulatory affairs are critical to operations and strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T13:04:44.426397+00:00","company_name":"Vera Therapeutics, Inc.","ticker":"VERA","filing_date":"2026-07-09"}]}